GeneReach Biotechnology Corp.(TW:4171)
NT$15.50+0.05 (+0.32%)
TW:4171
GeneReach Biotechnology Corp. financials statements
NT$15.50
At close:+0.05 (+0.32%)
GeneReach Biotechnology Corp. (4171) Ratios
GeneReach Biotechnology Corp. Ratios
TW:4171's free cash flow for Q2 2026 was NT$-5.54M. For the 2026 fiscal year, TW:4171's free cash flow was decreased by NT$-8.04M and operating cash flow was NT$2.50M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 2.41 | 2.48 | 3.07 | 2.78 | 4.24 |
| Quick Ratio | 2.25 | 2.33 | 2.74 | 2.17 | 3.28 |
| Cash Ratio | 0.85 | 0.46 | 1.05 | 1.94 | 2.38 |
| Solvency Ratio | -0.14 | -0.13 | -0.31 | 0.55 | 0.73 |
| Operating Cash Flow Ratio | -0.07 | -0.10 | -0.19 | 0.93 | 1.25 |
| Short-Term Operating Cash Flow Coverage | -0.10 | -0.13 | -0.26 | 1.34 | 4.29 |
| Net Current Asset Value | NT$ 199.82M | NT$ 253.67M | NT$ 318.43M | NT$ 550.85M | NT$ 584.19M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.26 | 0.26 | 0.22 | 0.25 | 0.23 |
| Debt-to-Equity Ratio | 0.38 | 0.38 | 0.31 | 0.38 | 0.38 |
| Debt-to-Capital Ratio | 0.28 | 0.28 | 0.24 | 0.27 | 0.27 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.01 | 0.17 |
| Financial Leverage Ratio | 1.50 | 1.49 | 1.41 | 1.52 | 1.60 |
| Debt Service Coverage Ratio | -0.04 | -0.24 | -0.62 | 1.06 | 5.04 |
| Interest Coverage Ratio | -12.28 | -22.11 | -39.79 | 42.02 | 76.75 |
| Debt to Market Cap | 0.13 | 0.11 | 0.07 | 0.09 | 0.08 |
| Interest Debt Per Share | 4.06 | 4.85 | 4.57 | 7.12 | 6.98 |
| Net Debt to EBITDA | -6.29 | -4.48 | -0.28 | -1.01 | -0.50 |
| Profitability Margins | |||||
| Gross Profit Margin | 69.14% | 57.28% | 12.23% | 65.34% | 73.81% |
| EBIT Margin | -34.31% | -53.78% | -94.29% | 37.20% | 47.00% |
| EBITDA Margin | -3.77% | -17.58% | -63.73% | 45.73% | 53.42% |
| Operating Profit Margin | -34.31% | -63.55% | -101.70% | 37.05% | 47.50% |
| Pretax Profit Margin | -50.04% | -56.65% | -96.84% | 36.32% | 46.38% |
| Net Profit Margin | -47.38% | -57.50% | -73.75% | 29.51% | 37.21% |
| Continuous Operations Profit Margin | -48.52% | -59.90% | -75.56% | 29.00% | 36.61% |
| Net Income Per EBT | 94.69% | 101.50% | 76.15% | 81.26% | 80.24% |
| EBT Per EBIT | 145.83% | 89.15% | 95.23% | 98.03% | 97.64% |
| Return on Assets (ROA) | -12.52% | -11.13% | -14.14% | 13.65% | 22.36% |
| Return on Equity (ROE) | -18.80% | -16.56% | -19.98% | 20.73% | 35.88% |
| Return on Capital Employed (ROCE) | -11.75% | -15.87% | -23.63% | 22.47% | 34.18% |
| Return on Invested Capital (ROIC) | -9.29% | -12.92% | -15.84% | 14.64% | 25.36% |
| Return on Tangible Assets | -12.74% | -11.26% | -14.29% | 13.73% | 22.49% |
| Earnings Yield | -10.27% | -7.21% | -7.38% | 7.30% | 9.93% |
| Efficiency Ratios | |||||
| Receivables Turnover | 5.60 | 4.63 | 9.74 | 13.33 | 5.15 |
| Payables Turnover | 67.43 | 44.98 | 348.99 | 322.51 | 38.70 |
| Inventory Turnover | 2.21 | 2.35 | 2.94 | 1.10 | 0.99 |
| Fixed Asset Turnover | 0.82 | 0.57 | 0.51 | 1.69 | 2.51 |
| Asset Turnover | 0.26 | 0.19 | 0.19 | 0.46 | 0.60 |
| Working Capital Turnover Ratio | 0.73 | 0.53 | 0.41 | 0.95 | 1.39 |
| Cash Conversion Cycle | 225.20 | 225.99 | 160.70 | 357.36 | 430.83 |
| Days of Sales Outstanding | 65.13 | 78.84 | 37.47 | 27.38 | 70.86 |
| Days of Inventory Outstanding | 165.48 | 155.26 | 124.28 | 331.11 | 369.41 |
| Days of Payables Outstanding | 5.41 | 8.11 | 1.05 | 1.13 | 9.43 |
| Operating Cycle | 230.61 | 234.11 | 161.75 | 358.49 | 440.27 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.24 | -0.40 | -0.67 | 6.22 | 6.07 |
| Free Cash Flow Per Share | -0.35 | -0.55 | -1.05 | 5.35 | 5.80 |
| Dividend Paid and CapEx Coverage Ratio | -2.18 | -0.95 | -0.42 | 1.38 | 2.19 |
| Capital Expenditure Coverage Ratio | -2.18 | -2.74 | -1.64 | 7.09 | 22.10 |
| Operating Cash Flow Coverage Ratio | -0.06 | -0.09 | -0.15 | 0.89 | 0.88 |
| Operating Cash Flow to Sales Ratio | -0.06 | -0.11 | -0.17 | 0.48 | 0.34 |
| Free Cash Flow Yield | -1.88% | -1.93% | -2.69% | 10.12% | 8.78% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -9.74 | -13.77 | -13.56 | 13.71 | 10.08 |
| Price-to-Sales (P/S) Ratio | 4.62 | 7.97 | 9.99 | 4.04 | 3.75 |
| Price-to-Book (P/B) Ratio | 1.83 | 2.30 | 2.71 | 2.84 | 3.61 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -53.13 | -51.94 | -37.17 | 9.88 | 11.39 |
| Price-to-Operating Cash Flow Ratio | -77.48 | -70.88 | -58.24 | 8.48 | 10.87 |
| Price-to-Earnings Growth (PEG) Ratio | 1.35 | 0.49 | 0.08 | -0.33 | 0.22 |
| Enterprise Value Multiple | -128.82 | -49.82 | -15.95 | 7.84 | 6.52 |
| Enterprise Value | 1.13B | 1.81B | 2.29B | 2.69B | 3.53B |
| EV to EBITDA | -128.82 | -49.82 | -15.95 | 7.84 | 6.52 |
| EV to Sales | 4.85 | 8.76 | 10.17 | 3.58 | 3.48 |
| EV to Free Cash Flow | -55.86 | -57.08 | -37.84 | 8.75 | 10.58 |
| EV to Operating Cash Flow | -81.46 | -77.89 | -59.28 | 7.52 | 10.10 |
| Tangible Book Value Per Share | 10.17 | 12.41 | 14.79 | 19.03 | 18.76 |
| Shareholders’ Equity Per Share | 10.27 | 12.48 | 14.48 | 18.58 | 18.27 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.03 | -0.06 | 0.22 | 0.20 | 0.21 |
| Revenue Per Share | 4.07 | 3.59 | 3.92 | 13.05 | 17.61 |
| Net Income Per Share | -1.93 | -2.07 | -2.89 | 3.85 | 6.55 |
| Tax Burden | 0.95 | 1.02 | 0.76 | 0.81 | 0.80 |
| Interest Burden | 1.46 | 1.05 | 1.03 | 0.98 | 0.99 |
| Research & Development to Revenue | 0.31 | 0.39 | 0.27 | 0.08 | 0.06 |
| SG&A to Revenue | 0.56 | 0.84 | 0.77 | 0.25 | 0.20 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.13 | 0.20 | 0.23 | 1.31 | 0.74 |
Currency in TWD
